School of Medicine, Universidad Científica del Sur, Lima, Peru.
Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru.
Lupus Sci Med. 2020 Feb 5;7(1):e000366. doi: 10.1136/lupus-2019-000366. eCollection 2020.
Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined.
To determine whether serum uric acid levels are associated with new damage in patients with SLE.
This is a longitudinal study of patients with SLE from the Almenara Lupus Cohort, which began in 2012. At each visit, demographic and clinical characteristics were evaluated, such as activity (Systemic Lupus Erythematosus Disease Activity Index-2K or SLEDAI-2K) and cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index or SDI). Treatment (glucocorticoids, immunosuppressive drugs and antimalarials) was also recorded. Univariable and multivariable Cox regression models were used to determine the impact of serum uric acid levels on the risk of new damage.
We evaluated 237 patients, with a mean age (SD) at diagnosis of 35.9 (13.1) years; 220 patients (92.8%) were women, and the duration of the disease was 7.3 (6.6) years. The mean SLEDAI-2K and SDI scores were 5.1 (4.2) and 0.9 (1.3), respectively. Serum uric acid level was 4.5 (1.4) mg/dL. Follow-up time was 3.1 (1.3) years, and 112 (47.3%) patients accrued damage during follow-up. In univariable and multivariable analyses, serum uric acid levels were associated with new damage (HR=1.141 (95% CI 1.016 to 1.282), p=0.026; HR=1.189 (95% CI 1.025 to 1.378), p=0.022, respectively).
Higher serum uric acid levels are associated with global damage in patients with SLE.
已有研究表明，血清尿酸水平可预测系统性红斑狼疮（SLE）患者的心血管、肺部、神经和肾脏疾病发病率。然而，其在这些患者累积性全身损伤中的作用尚未确定。
确定血清尿酸水平是否与 SLE 患者的新损伤相关。
这是一项来自于 2012 年开始的 Almenara 狼疮队列的 SLE 患者的纵向研究。在每次就诊时，评估了患者的人口统计学和临床特征，如疾病活动度（SLE 疾病活动指数 2.0 版或 SLEDAI-2K）和累积损伤（系统性红斑狼疮国际合作临床组/美国风湿病学会损伤指数或 SDI）。还记录了治疗（糖皮质激素、免疫抑制剂和抗疟药）情况。使用单变量和多变量 Cox 回归模型来确定血清尿酸水平对新损伤风险的影响。
我们评估了 237 例患者，诊断时的平均年龄（标准差）为 35.9（13.1）岁；220 例（92.8%）为女性，疾病病程为 7.3（6.6）年。SLEDAI-2K 和 SDI 评分的平均值分别为 5.1（4.2）和 0.9（1.3）。血清尿酸水平为 4.5（1.4）mg/dL。随访时间为 3.1（1.3）年，112 例（47.3%）患者在随访期间发生了损伤。单变量和多变量分析均显示，血清尿酸水平与新损伤相关（HR=1.141（95%CI 1.016 至 1.282），p=0.026；HR=1.189（95%CI 1.025 至 1.378），p=0.022）。
血清尿酸水平升高与 SLE 患者的全身损伤有关。
